ExScientia Ltd

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The firm has designed three drugs that are in phase 1 human clinical trials. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ExScientia reports robust Q4 earnings, poised for precision medicine growth

ExScientia's Q4 2022 earnings call highlighted strong financial performance, key collaborations, and advancements in pipeline programs. The company's focus on AI-driven precision medicine and solid cash position bode well for future growth. Challenges in program management and cost control exist, but opportunities for innovation and partnerships are abundant.

ExScientia reports 15% revenue growth, poised for precision medicine leadership

ExScientia Ltd delivered strong financial performance with a 15% increase in quarterly revenue and a robust cash position, driven by successful product launches and cost-saving initiatives.
The company's focus on personalized medicine, innovative product development, and strategic financial management positions it well for future growth and market leadership.
While facing challenges in molecule differentiation and cost efficiency, ExScientia has opportunities to leverage biomarkers, advance clinical programs, and expand market presence.

ExScientia advances clinical trials and precision medicine with strong financials

ExScientia's Q2 2023 earnings call showcased progress in clinical trials, precision medicine, and AI integration, supported by a strong financial position.
The company's focus on innovation, cost efficiency, and strategic partnerships positions them well for future growth and advancements in drug discovery.
Challenges lie in managing milestone payments, operational complexities, and staying competitive through biologics investments and partnerships.
Opportunities abound in expanding collaborations, attracting industry interest, and unveiling advancements in biologics for pipeline growth from 2024 onwards.

ExScientia excels in Q3, poised for growth in precision medicine

ExScientia's Q3 performance reflects progress in oncology programs, financial strength, and a focus on precision drug design and partnerships.
The company's strengths lie in its robust cash position, innovative approach to drug design, and operational efficiency influenced by past projects.
Challenges include market adaptability, program prioritization, and maintaining competitiveness, while opportunities exist in advancing the pipeline and leveraging partnerships for growth.

ExScientia reports robust Q4 earnings, eyes growth through innovation

ExScientia's Q4 2023 earnings call showcases strong financial and operational performance.
The company's focus on innovation, partnerships, and efficiency drives growth.
Challenges include competition, innovation sustainability, and quality maintenance.
Opportunities lie in business development, automation, and efficient drug creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

OXFORD, U.K.--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the appointment of Parker Moss as Executive Vice President, Corporate Development, effective January, 2024. In this newly established role, Parker will lead the creation and execution of a focused corporate development strategy to strengthen further and create new market opportunities for the company's precision medicine, clinical and tech innovation platforms, with a particular focus on oncology. Reporting to CEO Andr.

Parker Moss to Join Exscientia as EVP, Corporate Development

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced two abstracts to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023 from October 20-24, 2023 in Madrid, Spain. “We are excited to share new preclinical data on our precision-designed LSD1 and MALT1 inhibitors, which we introduced to our oncology pipeline earlier this year,” said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia. “We believe t.

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023

The consensus price target hints at a 99.1% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 99.07% Upside in Exscientia PLC Sponsored ADR (EXAI): Here's What You Should Know

Exscientia PLC Sponsored ADR (EXAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Exscientia PLC Sponsored ADR (EXAI) Stock Jumps 13.5%: Will It Continue to Soar?

OXFORD, U.K.--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today provided an update on its pipeline prioritisation strategy designed to further strengthen the Company's focus, investment and infrastructure on programmes of greatest potential for differentiation and value creation. Exscientia has built a highly efficient and versatile AI-led drug discovery platform. To date, its platform has yielded eight differentiated clinical development candidates across a variety of therapeutic areas, and.

Exscientia Details Pipeline Prioritisation Strategy

Exscientia PLC Sponsored ADR (EXAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -33.28% in 4 Weeks, Here's Why Exscientia PLC Sponsored ADR (EXAI) Looks Ripe for a Turnaround

Merck KGaA

Frontier IP Group PLC (AIM:FIPP), a firm specialising in the commercialisation of intellectual property, announced in an RNS today that its portfolio company Exscientia has entered into a collaboration with Merck to discover novel small molecule drug candidates in the fields of oncology, neuroinflammation, and immunology. Under the terms of the agreement, Exscientia will receive an upfront payment of $20 million from Merck.

Frontier portfolio company signs collaboration deal with Merck

Exscientia plc has partnered with Merck KGaA for AI-powered drug discovery in complex disease segments, solidifying its industry positioning. AI is gaining traction in the healthcare industry, with projections estimating the AI drug discovery market to reach $909 billion by 2030. AI is revolutionizing the drug discovery process by speeding up target identification, predicting efficacy, and reducing the need for physical testing.

Exscientia: Merck Deal Further Cements Industry Positioning, Reiterate Buy

Exscientia PLC shares climbed as much as 30% in pre-market trading on Wednesday after the precision-medicine company announced a new, multi-year collaboration with German science and technology company Merck KGaA, which could be worth hundreds of millions of dollars.  The collaboration will involve using Exscientia's AI-driven precision drug design and discovery capabilities to discover novel small-molecule drug candidates across oncology, neuroinflammation and immunology, according to the company.

Exscientia stock surges on Merck KGaA partnership

The U.S.-listed shares of Exscientia PLC EXAI soared 28.5% toward a record one-day gain, and enough to pace all premarket gainers on major U.S. exchanges, after the U.K.-based precision medicine company announced a collaboration with Germany-based Merck KGaA MKKGY XE:MRK for the discovery of drug candidates across oncology, neuroinflammation and immunology. The multi-year collaboration will utilize Exscientia's drug design and discovery capabilities, which are driven by use of artificial intelligence.

Exscientia's stock rockets toward a record gain after AI-driven drug discovery collaboration with Germany's Merck KGaA

OXFORD, U.K.--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Merck KGaA, Darmstadt, Germany focused on the discovery of novel small molecule drug candidates across oncology, neuroinflammation and immunology. The multi-year collaboration will utilise Exscientia's AI-driven precision drug design and discovery capabilities while leveraging Merck KGaA, Darmstadt, Germany's disease expertise in oncology and neuroinflammation, clinical development capabilities.

Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany

Recursion Pharmaceuticals

Schrodinger 

Schrödinger uses AI to drive revenue for both of its segments. Recursion got a big boost from computer chipmaker Nvidia.

3 AI Drug Discovery Stocks to Watch

GE HealthCare Technologies Inc

Intuitive Surgical

Med tech stocks are ripe for growth due to the advent of artificial intelligence ( AI ). AI is going to improve healthcare overall.

3 Med Tech Stocks That the AI Boom Will Only Help

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in September: 2023 Wells Fargo Healthcare Conference. Fireside chat on Thursday, September 7, 2023, at 3:45 p.m. EDT (8:45 p.m. BST) in Boston, Massachusetts Morgan Stanley Global Healthcare Conference 2023. Formal presentation on Tuesday, September 12, 2023, at 8:10 a.m. EDT (1:10 p.m. BST) in New York, NY Live web.

Exscientia to Present at Upcoming Investor Conferences in September

Bristol-Myers

Artificial intelligence is changing the drug-discovery process by making it much faster and cheaper.  Traditionally, most biotech stock drug candidates fail.

Biotech Breakthroughs: 3 Companies on the Cusp of Major Discoveries

Exscientia plc (NASDAQ:EXAI ) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET Company Participants Sara Sherman - Vice President of Investor Relations Andrew Hopkins - Chief Executive Officer Mike Krams - Chief Quantitative Medicine Officer Nikolaus Krall - EVP, Precision Medicine Ben Taylor - CFO and Chief Strategy Officer Dave Hallett - Chief Scientific Officer Conference Call Participants Alec Stranahan - Bank of America Gaurav Goparaju - Berenberg Capital Markets Vikram Purohit - Morgan Stanley Operator Hello, everyone. My name is Abby and I'll be your conference operator today.

Exscientia plc (EXAI) Q2 2023 Earnings Call Transcript

OXFORD, U.K.--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2023, are summarised below. Exscientia will host a conference call Thursday, August 10 at 1:30 p.m. BST / 8:30 a.m. EDT. “In the first half of 2023, four molecules precision-designed by Exscientia advanced further into clinical trials, a significant achievement as we progress our growing pipe.

Exscientia Business Update for Second Quarter and First Half of 2023

Super Micro Computer

Many investors, including a significant number of very wealthy individuals and institutions, are becoming enthralled with AI stocks. According to Goldman Sachs (NYSE: GS ), up to $200 billion could be poured into the technology by 2025.

3 AI Stocks Billionaires Are Loading Up On

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) will report financial results for the second quarter ended June 30, 2023, on Thursday August 10, 2023, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company's website at investors.exscientia.ai. Alternatively.

Exscientia to Report Second Quarter 2023 Financial Results on August 10, 2023

Exscientia, a pioneer in AI-driven drug development, is using artificial intelligence to accelerate the discovery and preclinical phases of drug development. The company's stock traded higher after starting a Phase 1/2 trial for a new cancer therapy, demonstrating the potential of their AI platform. The underlying technology, pipeline, and strategic partnerships position Exscientia as a promising candidate for the future of medicine.

Exscientia Is Worth The AI-Driven Speculation

NVIDIA

Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.

Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist

GlaxoSmithKline

The pharmaceutical sector generates a huge $1.2 trillion of revenue globally, and the U.S. is by far the most lucrative country for drug makers in the world. Therefore, the profits of successful American pharmaceutical firms can be truly staggering.

3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes

RadNet

But some stocks in the biotech category are rising for a reason that's more common with techs, such as chipmaker Nvidia Corp. NASDAQ: NVDA or Microsoft Corp. NASDAQ: MSFT, which has made a significant investment in OpenAI, developer of ChatGPT.

Biotech & Healthcare Meet AI: Stocks Soar On Innovation Potential

News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. Nasdaq: NVDA into AI-powered drug discovery company  Recursion Pharmaceuticals Inc. NASDAQ: RXRX more than doubled share prices. It also shined the spotlight on AI-powered drug discovery and the potential for quicker, better and more personalized drug therapies being developed using AI.

Exscientia is the Sniper of the AI Drug Discovery Industry

OXFORD, England & VIENNA, Austria--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-1, a prospective observational study in ovarian cancer to investigate the relationship between ex vivo drug response (EVDR) in primary tumour-derived samples using the company's precision medicine platform and actual patient clinical response. This first of its kind observational study in solid tumours will run at multiple medical research centres in Europe with a focus on.

News for ExScientia Ltd Stock (EXAI)